Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 05
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Myriad Genetics Inc
MYGN
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$4.52
-0.0155
-0.34%
Dern. MÀJ: Oct 2, 7:59 PM
$4.52
-0.0155
-0.34%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Myriad Genetics Financials
Myriad Genetics (MYGN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Myriad Genetics Affirms FY2026 Sales Guidance of $770.000M-$790.000M vs $776.790M Est
Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $770.000 million-$790.000 million to $770.000 million-$790.000 million vs $776.790 million estimate.
Benzinga Newsdesk
Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know
Myriad Genetics stock fell after hours after weak Q2 results, lower guidance and an operating loss.
Tanya Rawat
PRO
Myriad Genetics Lowers FY2026 Sales Guidance from $860.000M-$880.000M to $770.000M-$790.000M vs $863.568M Est
Myriad Genetics (NASDAQ:MYGN) lowers FY2026 sales outlook from $860.000 million-$880.000 million to $770.000 million-$790.000 million vs $863.568 million estimate.
Benzinga Newsdesk
PRO
Myriad Genetics Q2 Adj. EPS $(0.25) Misses $(0.06) Estimate, Sales $190.700M Miss $206.029M Estimate
Benzinga Newsdesk
PRO
Myriad Genetics Affirms FY2026 Sales Guidance of $860.000M-$880.000M vs $864.099M Est
Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $860.000 million-$880.000 million to $860.000 million-$880.000 million vs $864.099 million estimate.
Benzinga Newsdesk
PRO
Myriad Genetics Q1 Adj. EPS $(0.09) Misses $(0.07) Estimate, Sales $200.400M Miss $202.484M Estimate
Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 200 percent decrease over losses of $(0.03) per share from
Benzinga Newsdesk
